Dr. Paul Stoffels, who serves as Johnson & Johnson’s chief scientific officer, will end his tenure on December 31.
Stoffels, who is also vice-chairman of J&J’s executive committee, was responsible for reinvigorating J&J’s Janssen pharmaceutical pipeline and was instrumental in developing a COVID-19 vaccine.
The company’s CEO and executive chairman, Alex Gorsky, is also retiring from the company, effective January 3, 2022.
Stoffels, a Belgian, intends to spend more time with his family in Europe.
Earlier in his career, Stoffels focused on tropical-disease research and antiviral drugs.
He co-founded the antiviral firm Tibotec-Virco, which Janssen acquired in 2002, paving the way to the company’s focus on HIV drugs.
Stoffels also had a passion for tackling tuberculosis and Ebola and pushed Janssen to develop treatments for them.
In 2020, St…